Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | Understanding aberrant signaling pathways to prevent resistance to JAK2 inhibitors in MPNs

Alessandro Lucchesi • 24 Oct 2022
SOHO Italy 2022
Myelofibrosis Myeloproliferative Neoplasms

In this video, Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the importance of understanding the signaling pathways involved in resistance to JAK2 inhibitors in myeloproliferative neoplasms (MPNs), and further highlights the important role of combination treatment approaches. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alessandro Lucchesi

1:08
Insights into disease-modifying agents being explored in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:00
A novel model being used to investigate thrombo-inflammation in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:47
Investigating the role of thrombo-inflammation in MPNs
Alessandro Lucchesi • 12 Oct 2022
1:46
Signaling pathways involved in drug resistance in MPNs
Alessandro Lucchesi • 12 Oct 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals